- Home
- OCC vs PRLD Comparison
OCC vs PRLD Comparison
Compare OCC & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCC
- PRLD
- Stock Information
- Founded
- OCC 1983
- PRLD 2016
- Country
- OCC United States
- PRLD United States
- Employees
- OCC N/A
- PRLD N/A
- Industry
- OCC Telecommunications Equipment
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- OCC Industrials
- PRLD Health Care
- Exchange
- OCC Nasdaq
- PRLD Nasdaq
- Market Cap
- OCC 71.9M
- PRLD 69.1M
- IPO Year
- OCC 1996
- PRLD 2020
- Fundamental
- Price
- OCC $8.01
- PRLD $1.46
- Analyst Decision
- OCC
- PRLD Strong Buy
- Analyst Count
- OCC 0
- PRLD 3
- Target Price
- OCC N/A
- PRLD $4.00
- AVG Volume (30 Days)
- OCC 72.1K
- PRLD 3.4M
- Earning Date
- OCC 12-22-2025
- PRLD 11-12-2025
- Dividend Yield
- OCC N/A
- PRLD N/A
- EPS Growth
- OCC N/A
- PRLD N/A
- EPS
- OCC N/A
- PRLD N/A
- Revenue
- OCC $72,694,849.00
- PRLD $7,000,000.00
- Revenue This Year
- OCC N/A
- PRLD N/A
- Revenue Next Year
- OCC N/A
- PRLD N/A
- P/E Ratio
- OCC N/A
- PRLD N/A
- Revenue Growth
- OCC 12.67
- PRLD N/A
- 52 Week Low
- OCC $2.02
- PRLD $0.61
- 52 Week High
- OCC $11.50
- PRLD $4.22
- Technical
- Relative Strength Index (RSI)
- OCC 48.42
- PRLD 49.20
- Support Level
- OCC $7.10
- PRLD $1.17
- Resistance Level
- OCC $8.26
- PRLD $4.19
- Average True Range (ATR)
- OCC 0.72
- PRLD 0.38
- MACD
- OCC -0.03
- PRLD -0.07
- Stochastic Oscillator
- OCC 35.31
- PRLD 9.51
About OCC Optical Cable Corporation
Optical Cable Corp manufactures tight-buffered fiber optic & copper data communication cables, data communication connectivity solutions for enterprise markets, and customized solutions for specialty use & harsh environments. Its products and services include designs and customized products for specialty applications and harsh environments, cabling, connectors, patch cords, assemblies, racks, cabinets, datacom enclosures, patch panels, faceplates, and multi-media boxes. The company supplies its products and services to industries such as the military, industrial, mining, petrochemical, renewable energy and broadcast applications, and for the wireless carrier market.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.